Zevra THERAPEUTICS, Inc. (ZVRA) intrinsic value & 10-year financials
Zevra THERAPEUTICS, Inc. (ZVRA) has a Graham intrinsic value of $44.84 per share. At $9.94 on Oct 17, 2026, the stock trades 78% below that value. Over the last 10 fiscal years revenue grew 42.3% a year to $106.5M, with an average return on invested capital of -484.8%.
- Graham intrinsic value
- $44.84
- Share price (Oct 17, 2026)
- $9.94
- Price vs Graham value
- 78% below
- Market cap
- $569.2M
- Revenue (FY2025)
- $106.5M
- Revenue growth (10-yr CAGR)
- 42.3%
- ROIC (10-yr avg)
- -484.8%
- Free cash flow (FY2025)
- -$2.4M
ZVRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $106.5M | $83.2M | $1.35 | -$2.4M | -59.1% | -54.7% |
| FY2024 | $23.6M | -$105.5M | -$2.28 | -$69.7M | -368.5% | -193.1% |
| FY2023 | $27.5M | -$46.0M | — | -$33.8M | -180.6% | -217.9% |
| FY2022 | $10.5M | -$41.5M | — | -$18.8M | -406.4% | -224.4% |
| FY2021 | $28.6M | -$8.6M | -$2.11 | $10.3M | 27.0% | 105.7% |
| FY2020 | $13.3M | -$12.8M | -$3.21 | -$2.0M | -42.2% | -5857.7% |
| FY2019 | $12.8M | -$24.5M | — | -$23.8M | -158.4% | 2067.0% |
| FY2018 | $0 | -$56.5M | — | -$54.2M | — | -536.2% |
| FY2017 | — | -$43.4M | — | -$33.3M | — | -136.9% |
| FY2016 | — | -$16.5M | — | -$30.4M | — | 200.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ZEVRA THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ZEVRA THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -13.4% ROIC.
ZEVRA THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ZEVRA THERAPEUTICS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $44.84 per share.